Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy

Hengfeng Yuan, Wen Jiang, Christina A. Von Roemeling, Yaqing Qie, Xiujie Liu, Yuanxin Chen, Yifan Wang, Robert E. Wharen, Kyuson Yun, Guojun Bu, Keith L. Knutson, Betty Y.S. Kim

Research output: Contribution to journalArticlepeer-review

77 Scopus citations

Abstract

Tumour-targeted immunotherapy offers the unique advantage of specific tumouricidal effects with reduced immune-associated toxicity. However, existing platforms suffer from low potency, inability to generate long-term immune memory and decreased activities against tumour-cell subpopulations with low targeting receptor levels. Here we adopted a modular design approach that uses colloidal nanoparticles as substrates to create a multivalent bi-specific nanobioconjugate engager (mBiNE) to promote selective, immune-mediated eradication of cancer cells. By simultaneously targeting the human epidermal growth factor receptor 2 (HER2) expressed by cancer cells and pro-phagocytosis signalling mediated by calreticulin, the mBiNE stimulated HER2-targeted phagocytosis and produced durable antitumour immune responses against HER2-expressing tumours. Interestingly, although the initial immune activation mediated by the mBiNE was receptor dependent, the subsequent antitumour immunity also generated protective effects against tumour-cell populations that lacked the HER2 receptor. Thus, the mBiNE represents a new targeted, nanomaterial-immunotherapy platform to stimulate innate and adaptive immunity and promote a universal antitumour response.

Original languageEnglish (US)
Pages (from-to)763-769
Number of pages7
JournalNature Nanotechnology
Volume12
Issue number8
DOIs
StatePublished - Aug 1 2017

ASJC Scopus subject areas

  • Bioengineering
  • Atomic and Molecular Physics, and Optics
  • Biomedical Engineering
  • General Materials Science
  • Condensed Matter Physics
  • Electrical and Electronic Engineering

Fingerprint

Dive into the research topics of 'Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy'. Together they form a unique fingerprint.

Cite this